Literature DB >> 17218027

Role of c-fos gene in vasoactive intestinal peptide promoted synthesis of pulmonary surfactant phospholipids.

Lian Li1, Hua She, Shao-Jie Yue, Xiao-Qun Qin, Cha-Xiang Guan, Hui-Jun Liu, Zi-Qiang Luo.   

Abstract

We previously reported that vasoactive intestinal peptide (VIP) promoted synthesis of phosphatidylcholine (PC) in alveolar type II (ATII) cells. But the intracellular mechanism for this effect was unknown. In this work, we investigated the intracellular signal transduction pathway for VIP promoted synthesis of PC, the major lipid component of pulmonary surfactant (PS), by using an antagonist of VIP receptors, inhibitor of protein kinase C (PKC) and antisense oligonucleotides (AS-ODN) for c-fos oncogene. Our results showed that: 1 in circle [D-P-Cl-Phe(6)-Leu(17)]-VIP (10(-6) mol/l), an antagonist of VIP receptors, could decrease the quantity of [(3)H] choline incorporation, microsomal choline-phosphate cytidylyltransferase (CCT) mRNA expression and CCT activity induced by VIP (10(-8) mol/l) in cultured lung explants to the control levels; 2 in circle VIP (10(-8) mol/l) upregulated c-Fos protein expression in ATII cells. AS-ODN for c-fos oncogene (9x10(-6) mol/l) could block the elevation of [(3)H] choline incorporation, microsomal CCT mRNA expression and CCT activity induced by VIP in cultured lung explants and in ATII cells; 3 in circle H7 (10(-5) mol/l), a PKC inhibitor could also reduce VIP induced [(3)H] choline incorporation, microsomal CCT mRNA expression and CCT activity in cultured lung explants and in ATII cells. These results demonstrated that VIP receptors, PKC and c-Fos protein played important roles in the signaling pathway through which VIP promoted the synthesis of PC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218027     DOI: 10.1016/j.regpep.2006.11.027

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  3 in total

1.  The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.

Authors:  Jihad Georges Youssef; Philip Lavin; David A Schoenfeld; Richard A Lee; Rainer Lenhardt; David J Park; Javier Perez Fernandez; Melvin L Morganroth; Jonathan C Javitt; Dushyantha Jayaweera
Journal:  Crit Care Med       Date:  2022-08-29       Impact factor: 9.296

2.  Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide.

Authors:  Jihad Georges Youssef; Mohammad Z Bitar; Faisal Zahiruddin; Mukhtar Al-Saadi; Mahmoud Elshawwaf; Simon Yau; Ahmad Goodarzi; Jonathan C Javitt
Journal:  Crit Care Explor       Date:  2022-01-05

3.  Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial.

Authors:  Maria Boesing; Kristin Abig; Michael Brändle; Martin Brutsche; Emanuel Burri; Björn C Frye; Stéphanie Giezendanner; Jan C Grutters; Philippe Haas; Justian Heisler; Fabienne Jaun; Anne B Leuppi-Taegtmeyer; Giorgia Lüthi-Corridori; Joachim Müller-Quernheim; Reto Nüesch; Wolfgang Pohl; Frank Rassouli; Jörg D Leuppi
Journal:  Trials       Date:  2022-09-20       Impact factor: 2.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.